ArticleJACC. Basic to translational science2026
CXCL10 Regulates Pressure Overload-Induced Heart Failure.
Article in JACC. Basic to translational science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Interleukin-6 as an Oral-Vascular Inflammatory Bridge: Integrating CXCL10 and Haptoglobin 2-2 into a Potential Model of Periodontitis-Associated Cardiovascular Risk.International journal of molecular sciences · 2026Review
- T Cell Polarization in Heart Failure: Any Flavor, as Long as It Is Th1.JACC. Basic to translational science · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
Heart failure is a syndrome where immune cells play a crucial role in its development and progression. Although the recruitment of T cells driven by C-X-C motif chemokine receptor 3 activation has been reported, the specific contribution of C-X-C motif chemokine ligand 10 (CXCL10), one of its ligands, remains unclear. Here, we investigate the role of CXCL10 in pressure overload-induced cardiac remodeling, both in the early phase of remodeling and during heart failure progression. We used the transverse aortic constriction model to induce pressure overload in mice and assessed the role of CXCL10 in cardiac remodeling. Our study shows that the genetic deletion of CXCL10 attenuates early cardiac remodeling and with more pronounced effects 6 weeks after transverse aortic constriction, as CXCL10-/- mice exhibit reduced hypertrophy and fibrosis and are protected from the development of cardiac dysfunction, which was observed in wild-type animals. Notably, CXCL10-/- mice do not show T-cell expansion and activation in the draining lymph nodes, particularly in the CD4+ T-cell subset. Using bone marrow chimeras, we show that CXCL10 from recruited macrophages accelerates pathologic cardiac remodeling. Our findings establish CXCL10 as a key mediator of heart failure, acting through immune cell recruitment and activation. These results suggest that targeting CXCL10 could provide a novel therapeutic strategy to mitigate inflammation-driven heart failure progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.